Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 4/20 | 0.35 |
| ▸ | CDK19 | Q9BWU1 | 4/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18072235 | 0.83 | TSHR (0.47) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL670308 | 0.81 | LMNA (0.51) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL16001316 | 0.80 | TSHR (0.45) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL23131110 | 0.80 | LMNA (0.47) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL9963258 | 0.78 | CYP2D6 (0.48) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL16614241 | 0.77 | LMNA (0.45) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL22174114 | 0.76 | LMNA (0.44) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL371222 | 0.75 | USP2 (0.45) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL1096010 | 0.75 | LMNA (0.55) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL18848901 | 0.74 | LMNA (0.45) | LMNACHRM2ADRA2ACYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072585-B2 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200115341-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2020-04-16 | — | — | US | disclosed |
| US-10570094-B2 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190119211-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20170369443-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | LMNA 3629/4885CHRM2 1570/4885ADRA2A 2003/4885 |
| US-20190119211-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LMNA 175/4885CHRM2 3562/4885ADRA2A 2644/4885 |
| US-10570094-B2 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | LMNA 175/4885CHRM2 3562/4885ADRA2A 2644/4885 |
| US-20200115341-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LMNA 175/4885CHRM2 3562/4885ADRA2A 2644/4885 |
| US-11072585-B2 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | LMNA 175/4885CHRM2 3562/4885ADRA2A 2644/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | LMNA 3629/4885CHRM2 1570/4885ADRA2A 2003/4885 |
| US-20170369443-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LMNA 175/4885CHRM2 3562/4885ADRA2A 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.